Strategies for VTE Prophylaxis in Cancer for Inpatient, Outpatient Settings
Recommendations for venous thromboembolism prophylaxis in patients with cancer were discussed in an oral session at JADPRO Live 2022.
Diagnosis & Disease Information
Khorana Score Unable to Stratify Patients With Certain Cancer Subtypes by Risk of Venous Thromboembolism
Researchers sought to determine whether the Khorana score would be able to risk-stratify patients according to the 6-month risk of incident VTE.
Blood Type Linked to Venous Thromboembolism Risk in Patients With Cancer
Researchers sought to explore potential links between blood type, risk of venous thromboembolism, and cancer type in patients with cancer.
Oral Apixaban Valid, Patient-Friendly for Cancer-Associated Venous Thromboembolism
A new study suggests apixaban may be a potential treatment for cancer-associated venous thromboembolism, with possible variation in outcomes by cancer site.
Direct Oral Anticoagulants as Effective as Vitamin K Antagonists for Thromboembolic Events With Myeloproliferative Neoplasms
The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
Venous Thromboembolism Risk Steadily Increasing in Cancer
The risk for venous thromboembolism is steadily increasing among patients with cancer compared with the general population.
Venous Thromboembolism Rates in Patients With SARS-CoV-2 Infection
In a new study, researchers reported on the frequency of VTE among more than 6000 patients who tested positive for infection with SARS-CoV-2.
Notable Variation Exists in the Treatment of Serious VTE Events in Pediatric Leukemia
There might be notable variations among hematology, oncology, and bone marrow transplant practitioners when treating thrombotic events in children with leukemia.
Rivaroxaban May Be a Suitable Alternative to Low-Molecular Weight Heparin in Cancer-Associated Thrombosis
Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.
Molecular Profiling Can Assess Risk for Myeloproliferative Neoplasms With Splanchnic Vein Thrombosis
Researchers sought to markers that could identify high risk for splanchnic vein thrombosis among patients with MPNs.
- Loading...
Loading...
Next post in Myeloproliferative Neoplasms
Loading... 
Loading...